Answers are grounded in this paper and cite their sources.
Deficits in social cognition, including facial emotion recognition (FER), are present in individuals at clinical high-risk for psychosis (CHR-P). Altered GABAergic and glutamatergic signalling within corticolimbic circuitry has been proposed to underlie FER deficits in psychosis. We investigated FER performance and brain activation in CHR-P individuals, and whether pharmacological enhancement of GABAergic signalling with diazepam modulates these processes. In Study 1, 24 antipsychotic-naive CHR-P individuals and 24 healthy controls underwent fMRI while performing the Penn Emotion Recognition Task. In Study 2, 24 antipsychotic-naive CHR-P individuals participated in a randomised, double-blind, placebo-controlled, crossover study of 5mg diazepam versus placebo. Threat-related FER performance and neural activation were compared between groups and drug conditions. In Study 1, CHR-P individuals showed longer reaction times across emotions (n=22 vs n=23, p=0.01) and greater amygdala (pFWE=0.01) and hippocampal (pFWE=0.04) activation for neutral>fixation. Lower amygdala activation for threat>neutral (pFWE=0.03) and non-threat>neutral (pFWE=0.01), and lower hippocampal activation for non-threat>neutral (pFWE=0.04) may reflect this elevated response to neutral faces. Follow-up analyses showed lower insula (pFWE=0.01) and medial prefrontal cortex activation (pFWE=0.02) for threat>fixation. In Study 2, no significant drug effect on sensitivity was observed in the full sample (n=23), although secondary reduced-sample analyses, excluding one participant identified as influential, suggested improved overall sensitivity under diazepam (n=22; p=0.0499). After adjusting for global cerebral blood flow, diazepam reduced midcingulate cortex activation during neutral>fixation (pFWE=0.04). These findings highlight altered neural processing of neutral expressions in individuals at CHR-P, and suggest that aspects of emotion processing may be sensitive to GABAergic modulation.
No takes yet. Share an insight, caveat, or question.
Julius et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: